, Volume 20, Issue 4, pp 464–470 | Cite as

Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal

  • Margarida TeixeiraEmail author
  • Pedro Souteiro
  • Davide Carvalho



Prolactinomas are the most common functional pituitary tumour. Dopamine agonists (DA) are its principal treatment. The criteria that should guide therapy withdrawal and the factors that influence disease remission or relapse are not yet fully established. Our purpose is to evaluate the proportion of patients who attempted DA withdrawal, and to identify the factors that influence clinicians to try it. In addition, we aim to study the factors that are involved in prolactinoma remission/relapse after therapy withdrawal.


We retrospectively evaluated 142 patients with prolactinoma diagnosis who had been treated exclusively with DA. Firstly, the patients were divided in two groups, according to whether DA withdrawal had been attempted, or not, and the factors that might predict clinicians’ decision to discontinue the therapy were then analysed. Secondly, patients who attempted withdrawal were further divided into two subgroups, based on their remission or relapse status and predictors of remission were evaluated.


DA withdrawal was attempted in 35.2% of our patients. Females, subjects with lower initial serum prolactin (PRL) levels, those with microadenomas and those with longer treatment duration all had a higher probability of seeing their therapy discontinued. In the withdrawal group, the remission rate was 72%. Macroprolactinomas relapse more often than microprolactinomas (p < 0.05). The recurrence group had higher median initial serum PRL levels and a lower mean duration of therapy, however these variables did not reach statistical significance.


We found a low percentage of attempt of withdrawal of DA therapy in the subjects with prolactinoma. Our data confirms that DA therapy can be discontinued with a high remission rate. Tumour size was the main variable that affected the withdrawal outcome in our patients.


Prolactinoma Dopamine agonist Cabergoline Bromocriptine Withdrawal Recurrence Remission 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.


  1. 1.
    Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. doi: 10.1210/er.2005-9998 CrossRefPubMedGoogle Scholar
  2. 2.
    Kars M, Dekkers O, Pereira A, Romijn J (2010) Update in prolactinomas. Neth J Med 68(3):104–112PubMedGoogle Scholar
  3. 3.
    Romijn JA (2014) Hyperprolactinemia and prolactinoma. Handb Clin Neurol 124:185–195. doi: 10.1016/B978-0-444-59602-4.00013-7 CrossRefPubMedGoogle Scholar
  4. 4.
    Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf) 75(6):819–824. doi: 10.1111/j.1365-2265.2011.04136.x CrossRefGoogle Scholar
  5. 5.
    Kharlip J, Salvatori R, Yenokyan G, Wand G (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428–2436CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87(8):3578–3582CrossRefPubMedGoogle Scholar
  7. 7.
    Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72(4):507–511. doi: 10.1111/j.1365-2265.2009.03657.x CrossRefGoogle Scholar
  8. 8.
    Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265–273CrossRefGoogle Scholar
  9. 9.
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288CrossRefPubMedGoogle Scholar
  10. 10.
    Hu J, Zheng X, Zhang W, Yang H (2015) Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18(5):745–751. doi: 10.1007/s11102-014-0617-2 CrossRefPubMedGoogle Scholar
  11. 11.
    Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63(1):26–31. doi: 10.1111/j.1365-2265.2005.02293.x CrossRefGoogle Scholar
  12. 12.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi, G (2004) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Obstet Gynecol Surv 59(5):349–351CrossRefGoogle Scholar
  13. 13.
    Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51. doi: 10.1210/jc.2009-1238 CrossRefPubMedGoogle Scholar
  14. 14.
    Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1(3):555–574CrossRefPubMedGoogle Scholar
  15. 15.
    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S (2016) Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when? Pituitary 19(3):303–310CrossRefPubMedGoogle Scholar
  16. 16.
    Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi, G (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67(3):426–433. doi: 10.1111/j.1365-2265.2007.02905.x CrossRefGoogle Scholar
  17. 17.
    Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M (2012) Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15(1):25–29. doi: 10.1007/s11102-011-0303-6 CrossRefPubMedGoogle Scholar
  18. 18.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study 1. J Clin Endocrinol Metab 82(7):2102–2107PubMedGoogle Scholar
  19. 19.
    Colao A, Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma C, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331CrossRefPubMedGoogle Scholar
  20. 20.
    Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Presence of human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55(6):1178–1183CrossRefPubMedGoogle Scholar
  21. 21.
    Bassetti M, SPADA A, Pezzo G, Giannattasio G (1984) Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 58(2):268–273CrossRefPubMedGoogle Scholar
  22. 22.
    Landolt AM, Osterwalder V (1984) perivascular fibrosis in prolactinomas: is it increased by bromocriptine. J Clin Endocrinol Metab 58(6):1179–1183CrossRefPubMedGoogle Scholar
  23. 23.
    Jeffcoate W, Pound N, Sturrock N, Lambourne J (1996) Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45(3):299–303CrossRefGoogle Scholar
  24. 24.
    Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL (1984) Hyperprolactinemia, amenorrhea, and galactorrhea: a retrospective assessment of twenty-five cases. Ann Intern Med 100(1):115–121CrossRefPubMedGoogle Scholar
  25. 25.
    Sisam DA, Sheehan JP, Sheeler LR (1987) The natural history of untreated microprolactinomas. Fertil Steril 48(1):67–71CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Margarida Teixeira
    • 1
    Email author
  • Pedro Souteiro
    • 1
    • 2
    • 3
  • Davide Carvalho
    • 1
    • 2
    • 3
  1. 1.Faculty of MedicineUniversity of PortoPortoPortugal
  2. 2.Department of Endocrinology, Diabetes and MetabolismCentro Hospitalar S. JoãoPortoPortugal
  3. 3.Instituto de Investigação e Inovação em SaúdeUniversidade do PortoPortoPortugal

Personalised recommendations